-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110

Benzinga·03/30/2026 13:57:37
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target from $105 to $110.